Stabilization of Low Glass Transition Temperature Indomethacin Formulations: Impact of Polymer-Type and Its Concentration Rina J. Chokshi, Navnit H. Shah, Harpreet K. Sandhu, Ahmad W. Malick, Hossein Zia Journal of Pharmaceutical Sciences Volume 97, Issue 6, Pages 2286-2298 (June 2008) DOI: 10.1002/jps.21174 Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 1 Phase diagram of melt extrudates with EPO, PVP–VA, and PVPK30. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 2 PXRD comparing INM, physical mixture, and melt extrudate with EPO (drug:polymer 50:50). [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 3 PXRD of various melt extrudates with (a) EPO (b) PVP–VA (c) PVPK30. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 4 PXRD of the various melt extrudate with EPO in SGF after 72h. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 5 PXRD of the various melt extrudate with PVP–VA in SGF after 72h. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 6 Dissolution profile comparing various compositions of melt extrudates with EPO in SGF. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 7 Dissolution profile comparing various compositions of melt extrudates with PVP–VA in SIF. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 8 Dissolution profile comparing various compositions of melt extrudates with PVPK30 in SIF. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 9 PXRD of melt extrudates with EPO in SIF. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 10 PXRD of melt extrudates with PVPK30 in SGF. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 11 The dissolution profile comparing initial and 3 months 40°C/75% RH melt extrudate with EPO in SGF. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 12 The dissolution profile comparing initial and 3 months 40°C/75% RH melt extrudate with PVP–VA in SIF. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 13 The dissolution profile comparing initial and 3 months 40°C/75% RH melt extrudate with PVPK30 in SIF. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions
Figure 14 The moisture content of the melt extrudates comparing initial and stability samples. [Color figure can be seen in the online version of this article, available on the website, www.interscience.wiley.com.] Journal of Pharmaceutical Sciences 2008 97, 2286-2298DOI: (10.1002/jps.21174) Copyright © 2007 Wiley-Liss, Inc. Terms and Conditions